Monday broker round-up
13th Feb 2017 08:26
(ShareCast News) - Berkeley Group: Barclays reiterates Equal Weight with a target price of 3175p. Flybe Group: HSBC reiterates Buy with a target price of 55p. Esure Group: Berenberg maintains Sell with a target price of 193p. Berendsen: Citigroup reiterates Neutral with a target price of 930p. Sm
Read moreGlaxoSmithKline hits targets, earnings could slip due to generic rival
8th Feb 2017 12:03
(ShareCast News) - GlaxoSmithKline hit its full year earnings target on Wednesday but said growth in 2017 could be severely hampered by the looming prospect of generic competition to its key Advair respiratory drug. The group said US sales of Advair could decline by as much as 45% to £1bn at constan
Read moreSunday share tips: GlaxoSmithKline, Low&Bonar
5th Feb 2017 16:44
(ShareCast News) - GlaxoSmithKline chief Sir Andrew Witty will leave on a high note, leaving the company he joined in 1985 on a solid footing, and the outlook is still positive under incoming head Emma Walmsley, The Sunday Times´s Peter Evans said in his Inside the City column. A year and a half ago
Read moreFriday broker round-up
20th Jan 2017 09:51
(ShareCast News) - Whitbread: Barclays upgrades to Equal Weight with target price of 4150p. Inmarsat: Deutsche Bank reiterates Buy with a target price of 1020p. Halfords Group: HSBC reiterates Buy with a target price of 415p. Pets at Home: HSBC downgrades to Hold with a target price of 230p. Nati
Read moreGlaxoSmithKline nabs Astra's Luke Miels to head global pharma
19th Jan 2017 10:20
(ShareCast News) - The president of GlaxoSmithKline's global pharmaceuticals division, Abbas Hussain, is leaving the company later this year, to be replaced by AstraZeneca's Luke Miels. Miels, who is currently executive vice president of Astra's European business, will report to current chief execut
Read moreSunday newspaper round-up: Hard Brexit, Putin, Hammond
15th Jan 2017 16:35
(ShareCast News) - Theresa May will announce that Britain is seeking a clean and hard Brexit in a speech this week that will promise to create a "strong new partnership" with the European Union. The prime minister will finally lay her cards on the table, making clear that the UK is set to pull out o
Read moreGSK reports positive results from two-drug HIV regime study
20th Dec 2016 07:04
(ShareCast News) - Pharmaceutical giant GlaxoSmithKline said it achieved positive results from a phase three HIV study, which assessed the efficiency of a two-drug regimen. ViiVHealthcare, which is majority owned by the company with stakes owned by Pfizer and Shionogi, said the first phase three stu
Read moreGlaxoSmithKline starts phase III study of asthma treatment
19th Dec 2016 09:59
(ShareCast News) - GlaxoSmithKline has announced the start of a phase III study of its once-daily triple combination therapy fluticasone furoate/umeclidinium/vilanterol as a treatment for patients with asthma. The study, which will be conducted in partnership with Innoviva Inc, will compare the trea
Read moreTuesday broker round-up
13th Dec 2016 13:12
(ShareCast News) - British Land: Barclays reiterates overweight with a target price of 740p. GlaxoSmithKline: UBS reiterates neutral, 1600p target. Reckitt Benckiser: Jefferies reiterates buy with a 7750p target. GB Group: Berenberg reiterates buy with a 340p target. Great Portland Estates: Barcl
Read moreJapan approves GSK's bronchitis and emphysema drug
2nd Dec 2016 07:04
(ShareCast News) - The Japanese government has approved GlaxoSmithKilne and Nasdaq-listed Innoviva's drug which treats chronic bronchitis and pulmonary emphysema. Japan's Ministry of Health, Labour and Welfare approved the use of Relvar, which relieves symptoms of chronic obstructive pulmonary disea
Read moreThursday newspaper round-up: Pensions, Fitbit, Glaxo, Logica
1st Dec 2016 07:09
(ShareCast News) - Labour has vowed to protect pensioner benefits, free bus passes and the winter fuel payment until 2025 in an attempt to dent the overwhelming support for the Conservative party among older voters. The £3bn-a-year commitment comes just one week after Philip Hammond, the chancellor,
Read moreGlaxoSmithKline seeks European approval for shingles vaccine
25th Nov 2016 14:21
(ShareCast News) - GlaxoSmithKline announced the regulatory submission of a marketing authorisation application to the European Medicines Agency for approval of its candidate shingles vaccine, Shingrix. The phase III clinical trial of the vaccine - for the prevention of shingles in people over 50 an
Read moreGlaxoSmithKline starts Phase III studies of daprodustat for anaemia
24th Nov 2016 11:17
(ShareCast News) - GlaxoSmithKline has started a phase III development programme to investigate daprodustat for anaemia associated with chronic kidney disease. The programme includes two studies evaluating the safety and efficacy of daprodustat compared to recombinant human erythropoietin. ASCEND-D
Read moreGSK EGPA treatment meets endpoints in phase 3 study
23rd Nov 2016 07:24
(ShareCast News) - GlaxoSmithKline said on Wednesday that both co-primary endpoints and all secondary endpoints were met in a "pivotal" phase III study investigating the efficacy and safety of it smepolizumab treatment in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyan
Read moreGlaxoSmithKline files for triple COPD therapy 18 months early
21st Nov 2016 07:18
(ShareCast News) - GlaxoSmithKline has filed a US regulatory submission for a new three-drug inhaler treatment for patients with chronic obstructive pulmonary diseases such as chronic bronchitis and emphysema. The filing was achieved around 18 months earlier than originally planned, with a regulator
Read more